FDA approves first interchangeable biosimilar insulin product

The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D.
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
Related News Articles
Headline
The AHA July 16 announced five winners of the 2025 AHA Dick Davidson NOVA Award for their hospital-led collaborative efforts to improve community…
Headline
The Centers for Medicare & Medicaid Services June 27 announced the rollout of a 6-year technology-enabled prior authorization program pilot. Through…
Headline
AHA podcast: Food as Medicine — How Cleveland Clinic Is Nourishing Community HealthVickie Johnson, executive vice president and chief community officer at…
Headline
As part of Community Health Improvement Week June 9-13, two experts from Corewell Health share how an impactful health care ecosystem model is supporting local…
Headline
With June 9-13 being Community Health Improvement Week, three experts from HonorHealth discuss how the health care network is addressing community needs beyond…
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…